https://doi.org/10.55788/187f2b86
Prof. Joseph Sung (Lee Kong Chian School of Medicine, Singapore) pointed out in his presentation that AI-assisted colonoscopy has been shown to improve polyp detection and characterisation in colonoscopy [1]. However, data from large-scale, multicentre, randomised-controlled trials (RCTs) are still missing. This was the rationale for a multicentre, single-blind RCT in China including Hong Kong.
Recruited participants were randomised (1:1) to receive either AI-assisted or conventional coloscopy. Study participants were asymptomatic, 45–75 years old, and were undergoing colorectal carcinoma (CRC) screening either by direct screening colonoscopy or by a faecal immunochemical test (FIT)-based screening programme. IBD or a colonoscopy within 10 years were exclusion criteria. The AI system used was a deep convolution neural network trained and validated by 112,199 still images and a separate dataset of 21 colonoscopy videos. According to an independent validation, the system achieved both sensitivity and specificity of >89% in recognising polyps. “This AI device has an ordinary desktop computer size and can fit in any endoscopy tower,” said Prof. Sung. In the trial, high-definition colonoscopes, endoscopy processors, and monitors were used. However, neither electronic image enhancing function nor mucosal exposure devices were allowed.
The primary study outcome was the overall adenoma detection rate (ADR), the proportion of patients with at least one colorectal adenoma detected among all patients examined by an endoscopist. All adenomas (non-advanced adenomas, advanced adenoma, and CRC) were assessed.
Altogether, 3,059 participants were included in the intention-to-treat analysis. The ADR was significantly better in the AI group compared with the conventional colonoscopy (606 vs 499; P<0.001). “Even those with inadequate preparation benefitted from the AI-assisted colonoscopy,” Prof. Sung emphasised. A significant benefit was seen in both advanced and non-advanced, large and small adenoma, and proximal and distal adenoma. The only disadvantage was that the procedure itself took significantly longer with AI.
“AI should become standard of class in colonoscopy, because it does not only improve adenoma detection in general but also advanced adenoma, and thus can help in cancer prevention and will improve the outcome of patients,” Prof. Sung concluded.
- Sung JJ, et al. Artificial intelligence-assisted colonoscopy for colorectal cancer screening: a multicenter randomized controlled trial. Lecture 414, Digestive Disease Week 2022, 21–24 May, San Diego, CA, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections Next Article
Dietary intervention from your supermarket »
« Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections Next Article
Dietary intervention from your supermarket »
Table of Contents: DDW 2022
Featured articles
Too much hygiene: CD in later life?
IBD
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
IL-23 inhibition beneficial in maintenance treatment of UC
Positive outcomes for etrasimod in UC
Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation
Upper GI
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cannabis users need more sedation medication for gastroscopy
Preterm delivery and NICU admission are associated with the development of eosinophilic oesophagitis
Dupilumab promising as treatment for eosinophilic oesophagitis
Other Highlighted Research
AI-assisted colonoscopy improves adenoma detection
Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections
Oral microbes effective for prevention of recurrent Clostridium difficile infections
Octreotide therapy beats standard of care in GIADs
Improvement in hepatic steatosis but worse lipid profile after alcohol cessation
Normal BMI in NAFLD patients is associated with a higher risk of cardiovascular disease
COVID-19 increases the mortality rates of patients with ALD
Related Articles
January 18, 2021
Poor disease control: a risk factor for severe COVID-19
September 23, 2020
Treatment times of acute STEMI have increased with COVID-19 pandemic
September 22, 2020
Severe COVID-19 less common in patients with GI symptoms
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com